<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885066</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633338</org_study_id>
    <secondary_id>CALACASS-CAPERGEM</secondary_id>
    <secondary_id>ROCHE-CALACASS-CAPERGEM</secondary_id>
    <secondary_id>INCA-RECF0622</secondary_id>
    <secondary_id>EUDRACT-2007-005072-14</secondary_id>
    <nct_id>NCT00885066</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine given&#xD;
      together with capecitabine and erlotinib in treating patients with advanced pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum-tolerated dose of the combination of gemcitabine hydrochloride,&#xD;
           capecitabine, and erlotinib hydrochloride in patients with advanced pancreatic cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Analyze the limiting toxicities according to CTC.&#xD;
&#xD;
        -  Analyze the toxicity according to CTC.&#xD;
&#xD;
        -  Determine the recommended dose.&#xD;
&#xD;
        -  Determine the pharmacokinetic dosages of the three drugs.&#xD;
&#xD;
        -  Analyze interactions between the drugs.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive one course of chemotherapy comprising gemcitabine hydrochloride IV over 30&#xD;
      minutes on days 1, 8, and 15, oral capecitabine twice daily on days 1-21, and oral erlotinib&#xD;
      hydrochloride once daily on days 1-28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical or laboratory toxicities as assessed by CTC</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>gemcitabine, capecitabine, erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  No standard curative therapy available&#xD;
&#xD;
          -  Must have received prior first-line chemotherapy&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks&#xD;
&#xD;
          -  ANC ≥ 1.5 x 10^9/ L&#xD;
&#xD;
          -  Platelet count ≥ 130 x 10^9/ L&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Liver transaminases ≤ 1.5 times upper limit of normal (ULN) (≤ 5 times ULN in the&#xD;
             presence of liver metastases)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 130 mmol/L OR creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No intolerance or hypersensitivity to any of the drugs being tested&#xD;
&#xD;
          -  No history of interstitial lung disease&#xD;
&#xD;
          -  No history of severe cardiac disease&#xD;
&#xD;
          -  No serious uncontrolled infection&#xD;
&#xD;
          -  No rare hereditary disorders, i.e., galactosemia, lactase deficiency, or malabsorption&#xD;
             of glucose or galactose syndrome&#xD;
&#xD;
          -  Must not be deprived of liberty or under guardianship&#xD;
&#xD;
          -  Must not be on probation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior erlotinib hydrochloride&#xD;
&#xD;
          -  No concurrent potent inducers or inhibitors of cytochrome P450 or CYP3A4&#xD;
&#xD;
          -  More than 14 days since participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Francois</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 18, 2009</study_first_submitted>
  <study_first_submitted_qc>April 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>February 8, 2015</last_update_submitted>
  <last_update_submitted_qc>February 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

